Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.
Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.

**Title**: Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.  
**Publication Type**: Journal Article  
**Year of Publication**: 2011  
**Authors**: Guenaga, J, Dosenovic, P, Ofek, GA, Baker, D, Schief, WR, Kwong, PD  
**Journal**: PLoS One  
**Volume**: 6  
**Issue**: 1  
**Pagination**: e16074  
**Date Published**: 2011  
**ISSN**: 1932-6203  
**Keywords**: Antibodies, Neutralizing, B-Lymphocytes, Epitopes, HIV Antibodies, HIV Envelope Protein gp41  
**Abstract**: The HIV-1 envelope glycoproteins (Env) gp120 and gp41 mediate entry and are the targets for neutralizing antibodies. The gp41 2F5 epitope is a structurally defined and immunogen-conserved region of gp41. Here we report the generation of a vaccine platform that effectively focuses the humoral immune response on the structurally defined and immunogen-conserved HIV-1 2F5 epitope.  
**DOI**: 10.1371/journal.pone.0016074  
**Alternate Journal**: PLoS ONE  
**PubMed ID**: 21297864  
**PubMed Central ID**: PMC3027617  
**Grant List**: Intramural NIH HHS / United States